A new definition for metabolic associated fatty liver disease: an international expert consensus statement

Hepatology

Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients

J Gastroenterol Hepatol.

Gao F, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Chen YP, George J, Zheng MH

doi: 10.1111/jgh.15112.

Further Publications

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States

J Hepatol

Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A

doi: 10.1016/j.jhep.2021.07.035

Hepatology

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Liver Transpl

Younossi ZM

doi: 10.1002/lt.25003.

Further Publications

Metabolic dysfunction associated fatty liver disease improves detection of high liver stiffness: The rotterdam study

Hepatology

van Kleef L, Ayada I, Alferink L, Pan Q, de Knegt R

doi: 10.1002/hep.32131

Hepatology

Nonalcoholic Fatty Liver Disease Increases Risk of Incident Chronic Kidney Disease: a Systematic Review and Meta-Analysis

Metabolism.

Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G

doi: 10.1016/j.metabol.

Hepatology

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

J Gastroenterol Hepatol.

Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T

doi: 10.1111/jgh.15172.

Gastrointestinal Cancer

Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines

Lancet Gastroenterol Hepatol

Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan P, Mirza DF, Isaac J, Laing RW, Iyer SG, Chee CE, Yong WP, Muthiah MD, Panaro F, Sanabria J, Grothey A, Moodley K, Chau I, Chan ACY, Wang CC, Menon K, Sapisochin G, Hagness M, Dueland S, Line PD, Adam R

doi: 10.1016/S2468-1253(21)00219-3

Hepatology

Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study

J Clin Med.

van den Berg EH, Gruppen EG, Blokzijl H, Bakker SJL, Dullaart RPF

doi: 10.3390/jcm8122157.

COMMENTED

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease

Aliment Pharmacol Ther.

Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V

doi: 10.1111/apt.14853.

Related content

Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Metabolic dysfunction associated fatty liver disease improves detection of high liver stiffness: The rotterdam study

Nonalcoholic Fatty Liver Disease Increases Risk of Incident Chronic Kidney Disease: a Systematic Review and Meta-Analysis

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines

Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease